Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield 
Innate Pharma Reports 55% Revenue Drop and €49.2M Net Loss for 2025 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push 
Reflection AI Eyes $25 Billion Valuation in Massive $2.5 Billion Funding Round 
Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership 
9 Tips for Avoiding Tax Season Cyber Scams 
Democratic Attorneys General Sue Trump Administration Over CDC Childhood Vaccine Schedule Changes 
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology 
Global Flight Cancellations 2026: Middle East Air Travel Chaos Explained 
Pfizer has entered into a licensing agreement worth up to $6 billion with Chinese biopharmaceutical firm 3SBio Inc, aiming to advance a promising cancer treatment currently in clinical trials. The collaboration underscores Pfizer’s growing interest in oncology and its strategic push into the Asian pharmaceutical market.
Under the agreement, 3SBio will take charge of developing, manufacturing, and commercializing the investigational drug in China. The compound, still in trial phases, is designed to treat various cancers and tumors, though specific indications have not been disclosed. Pfizer retains rights outside of China and will receive milestone payments and royalties based on development progress and commercial performance.
This partnership highlights a trend of Western pharmaceutical giants teaming up with Chinese biotech firms to accelerate access to cutting-edge therapies in one of the world’s fastest-growing healthcare markets. For Pfizer, the deal not only strengthens its oncology portfolio but also aligns with its broader strategy of expanding its presence in emerging markets.
The deal’s structure includes upfront and milestone payments that could total $6 billion, signaling strong confidence in the drug’s potential. It also reflects Pfizer’s continued investment in targeted cancer therapies and biologics, which have become critical areas of growth amid increasing global demand.
By collaborating with 3SBio, a company with established R&D and commercial infrastructure in China, Pfizer leverages local expertise to navigate regulatory pathways and bring advanced treatments to Chinese patients faster. For 3SBio, the partnership provides access to innovative science and strengthens its oncology pipeline.
This move is part of Pfizer’s ongoing strategy to forge global alliances that accelerate innovation and deliver next-generation cancer treatments worldwide. With the global oncology market projected to surpass $500 billion by 2030, such partnerships are key to staying competitive and impactful in the pharmaceutical space.
